Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer

scientific article published on 20 May 2014

Locoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer is …
instance of (P31):
scholarly articleQ13442814

External links are
P6179Dimensions Publication ID1021016376
P356DOI10.1245/S10434-014-3767-6
P8608Fatcat IDrelease_umvmngze5zhrbblyxl2intiice
P698PubMed publication ID24841346

P50authorBetro T SadekQ39032327
P2093author name stringPauline T Truong
Alphonse G Taghian
Rita Abi Raad
Mina Shenouda
Cheryl S Alexander
David J Peterson
Bradley Wiksyk
P2860cites workHigh risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smallerQ24641848
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancerQ27824847
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogeneQ27860693
Molecular portraits of human breast tumoursQ28032461
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trialsQ29031162
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancerQ29616112
Younger age as a prognostic indicator in breast cancer: a cohort studyQ34003908
The impact of age on outcome in early-stage breast cancerQ34584831
Epidermal growth factor family receptors and inhibitors: radiation response modulatorsQ35042083
Triple-negative breast cancer is not a contraindication for breast conservationQ35111687
Age, breast cancer subtype approximation, and local recurrence after breast-conserving therapyQ35289587
Adjuvant trastuzumab in HER2-positive breast cancerQ35710898
Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapyQ37355667
Hormone receptor status influences the locoregional benefit of trastuzumab in patients with nonmetastatic breast cancerQ37467023
Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?Q37586016
Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotypeQ37965397
Effect of age on breast cancer outcomes in women with human epidermal growth factor receptor 2-positive breast cancer: results from a herceptin adjuvant trialQ39404724
The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: A paradigm for the development of other macromolecular markers-A reviewQ40442632
Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.Q42434873
Breast cancer subtypes and the risk of local and regional relapse.Q42468027
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancerQ43250044
Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomQ45081463
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trialQ46736552
Amplification of a novel v-erbB-related gene in a human mammary carcinomaQ48375434
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.Q53243856
Her2/neu-positive disease does not increase risk of locoregional recurrence for patients treated with neoadjuvant doxorubicin-based chemotherapy, mastectomy, and radiotherapy.Q53890280
Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer.Q54563619
P433issue11
P921main subjecttrastuzumabQ412616
P304page(s)3490-3496
P577publication date2014-05-20
P1433published inAnnals of Surgical OncologyQ2853069
P1476titleLocoregional recurrence and survival outcomes by type of local therapy and trastuzumab use among women with node-negative, HER2-positive breast cancer
P478volume21

Reverse relations

cites work (P2860)
Q36908374Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer
Q90049544Do early HER2-overexpression breast cancer patients benefit from undergoing neoadjuvant trastuzumab and mastectomy? A meta-analysis
Q36308052Her2 positivity and race predict higher mastectomy rates: a SEER database analysis
Q40382522Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy
Q50045468Molecular Subtypes and Local-Regional Control of Breast Cancer.
Q47939862Quality of life in patients with recurrent breast cancer after second breast-conserving therapy in comparison with mastectomy: the German experience
Q36754437Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice
Q54298427The Effect of Adjuvant Trastuzumab on Locoregional Recurrence of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Treated with Mastectomy.

Search more.